Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П.Сербского Минздрава России. 119992, Россия, Москва, Кропоткинский пер., д. 23
Список исп. литературыСкрыть список 1. American Academy of Sleep Medicine. International classification of sleep disorders, 3d ed.: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, 2014. 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-V). Washington, DC: American Psychiatric Association, 2013. 3. Morin CM, LeBlanc M, Belanger L et al. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry 2011; 56 (9): 540–8. 4. Leger D, Guilleminault C, Dreyfus JP et al. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000; 9: 35–42. 5. Morin CM, LeBlanc M, Daley M et al. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006; 7 (2): 123–30. 6. Ohayon MM, Reynolds CF. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD) Sleep Med 2009; 10 (9): 952–60. 7. Вейн А.М., Хехт К. Сон человека: Физиология и патология. М.: Медицина, 1989. / Vein A.M., Khekht K. Son cheloveka: Fiziologiia i patologiia. M.: Meditsina, 1989. [in Russian] 8. Голенков А.В., Полуэктов М.Г. Распространенность нарушений сна у жителей Чувашии (данные сплошного анкетного опроса). Korsakova/2011/6/11/NEV_2011_06_064. / Golenkov A.V., Poluektov M.G. Rasprostranennost' narushenii sna u zhitelei Chuvashii (dannye sploshnogo anketnogo oprosa). Korsakova/2011/6/11/NEV_2011_06_064. [in Russian] 9. Buysse DJ. Insomnia. JAMA 2013; 309: 706–16. 10. Morin CM, LeBlanc M, Grégoire JP, Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep 2009; 32: 55–64. 11. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997; 154 (10): 1417–23. 12. Chong Yi, Fryar CD, Gu Q. Prescription Sleep Aid Use Among Adults: United States, 2005–2010. Nat Health Nutr Exam Surv 2013; 127. 13. Schutte-Rodin S, Broch L, Buysse D et al. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J Clin Sleep Med 2008; 4 (5): 487–504. 14. Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol 2006. 15. Brzezinski A, Vangel MG, Wurtman RJ et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9 (1): 41–50. 16. Buscemi N, Vandermeer B et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332: 385. 17. Wang F, Li J, Wu C et al. The GABA(A) receptor mediates the hypnotic activity of melatonin in rats. Pharmacol Biochem Behav 2003; 74 (3): 573–8. 18. Mailliet F, Galloux P, Poisson D. Comparative effects of melatonin, zolpidem and diazepam on sleep, body temperature, blood pressure and heart rate measured by radiotelemetry in Wistar rats. Psychopharmacology (Berl) 2001; 156 (4): 417–26. 19. Wang F, Zou D, Li JC et al. The role of melatonin receptor and GABAA receptor in the sleeping time prolonged by melatonin in mice. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2003; 19 (4): 402–5. 20. Ochoa-Sanchez R, Comai S, Spadoni G et al. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states. Neurosci Lett 2014; 561: 156–61. Doi: 10.1016/j.neulet.2013.12.069. Epub 2014 Jan 7 21. Ochoa-Sanchez R, Comai S, Lacoste B et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci 2011; 31 (50): 18439–52. Doi: 10.1523/JNEUROSCI.2676-11.2011. 22. Comai S, Ochoa-Sanchez R, Gobbi G. Sleep-wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice. Behav Brain Res 2013; 243: 231–8. 23. Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation. Acad Sci 2010; 1200: 149–61; 24. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007; 8 (3): 171–81. 25. Mieda M et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004; 101: 4649–54. 26. Gotter AL, Garson SL, Stevens J et al. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014; 15: 109. 27. Fox SV, Gotter AL, Tye SJ et al. Quantitative Electroencephalography Within Sleep/Wake States Differentiates GABAA Modulators Eszopiclone and Zolpidem From Dual Orexin Receptor Antagonists in Rats. Neuropsychopharmacology 2013; 38: 2401–8. 28. Gotter AL, Winrow CJ et al. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013; 14: 90. 29. Tannenbaum PL, Stevens J, Renger JJ. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci 2014; 16. 30. Uslaner JM, Tye SJ, Eddins DM et al. 179ra44 Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013; 5 (179). 31. Uslaner JM et al. Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition. Sci Transl Med 2013; 5: 179ra44. 32. Ramirez AD, Gotter AL et al. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci 2013; 7: 254. 33. Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Exp Rev Clin Pharmacol 2014; 7 (6): 711–30. 34. Laudon M, Urade Y, Huang Z. A Novel Melatonin Agonist: Effects On Sleep And EEG Power Spectra In Rats. Sleep 2008; 31 (Abstr., Suppl. A34). 35. Yalkinoglu O, Zisapel N, Nir T. Phase-I study of the safety, tolerability, pharmacokinetics and sleep promoting activity of Neu-P11, a novel putative insomnia drug in healthy humans. Sleep 2010; 33: A220. 36. Laudon, M, Katz, A, Metzger, D et al. Tolerability, pharmacokinetic and pharmacodynamic evaluation of multiple ascending doses of Neu-P11 in insomnia patients. Sleep 2012; 35 (Abstr., Suppl. A221). 37. Neurim pharmaceuticals announces positive phase 2 clinical trial results of piromelatine for the treatment of insomnia Zurich, February 18, 2013. 38. Anaclet C, Parmentier R et al. Orexin/Hypocretin and Histamine: Distinct Roles in the Control of Wakefulness Demonstrated Using Knock-Out Mouse Models. J Neurosci 2009; 2604-09. 39. Lin JS, Sakai K, Vanni-Mercier G et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990; 523 (2): 325–30. 40. Gondard E, Anaclet C, Akaoka H et al. Enhanced Histaminergic Neurotransmission and Sleep-Wake Alterations, a Study in Histamine H3-Receptor Knock-Out Mice. Neuropsychopharmacology 2013; 38: 1015–31. 41. Lin JS, Sergeeva OA, Haas HL. Histamine H3 Receptors and Sleep-Wake Regulation. J Pharmacol Experim Ther 2011; 336 (1): 17–23. 42. Guo RX, Anaclet C, Roberts JC et al. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox−/−mice. Br J Pharmacol 2009; 157:104–117. 43. Parmentiera R, Anacleta C, Guhennecc C et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007; 73 (Issue 8, 15): 1157–71. 44. Inocente C, Arnulf I, Bastuji H et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 2012; 35 (2): 55–60.